← ANALYST RATINGS · TIPRANKS
TG Therapeutics (TGTX): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy0 Hold1 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $66.40, the highest $86.00, the lowest $21.00. The average is +23.0% from the last price of $53.97.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $78.00 | Buy | +44.5% | Reiterated | 21.09.26on TipRanks 13:55 | −1.0%next day +1.7% · 5 days −0.7% | ↗ |
| William Wood★★★★★★★★★★#3198 · hits 53% · avg +11.7% | B. Riley Securities | $86.00 | Buy | +59.3% | Reiterated | 02.09.26on TipRanks 09:10 | +1.0%next day −1.4% · 5 days −1.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $58.00 → $62.00+6.9% | Buy | +14.9% | Reiterated | 22.08.26on TipRanks 06:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $57.00 → $62.00+8.8% | Buy | +14.9% | Reiterated | 22.08.26on TipRanks 06:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $55.00 → $59.00+7.3% | Hold | +9.3% | Reiterated | 22.08.26on TipRanks 06:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $52.00 → $59.00+13.5% | Hold | +9.3% | Reiterated | 22.08.26on TipRanks 06:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $55.00 → $62.00+12.7% | Buy | +14.9% | Reiterated | 22.08.26on TipRanks 06:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $56.00 → $61.00+8.9% | Buy | +13.0% | Reiterated | 22.08.26on TipRanks 06:06 | — | |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $65.00 → $72.00+10.8% | Buy | +33.4% | Reiterated | 10.08.26on TipRanks Aug 11 08:07 | −1.2%next day +1.8% · 5 days +0.3% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $20.00 → $21.00+5.0% | Sell | −61.1% | Reiterated | 05.08.26on TipRanks 07:51 | +2.5%next day −0.5% · 5 days −1.1% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | $75.00 | Buy | +39.0% | Reiterated | 03.08.26on TipRanks Aug 4 01:20 | −12.7%next day +3.8% · 5 days +4.4% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $83.00 | Buy | +53.8% | Reiterated | 14.07.26on TipRanks 09:45 | −0.6%next day +2.4% · 5 days −1.2% | ↗ |
| Corinne Johnson★★★★★★★★★★#1634 · hits 55% · avg +11.6% | Goldman Sachs | $41.00 | Hold | −24.0% | Reiterated | 03.06.26on TipRanks Jun 4 07:50 | +10.2%next day +0.7% · 5 days +20.1% | ↗ |
| Eric Joseph★★★★★★★★★★#1258 · hits 52% · avg +11.4% | Citi | $46.00 → $49.00+6.5% | Buy | −9.2% | Reiterated | 03.11.25on TipRanks 15:50 | −3.3%next day +1.5% · 5 days −9.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering TG Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $69.17 at a price of $55.78 (+24.0%); now: $66.40 at $53.97 (+23.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 6 | 7 | 7 | 5 | 3 |
| Buy | 2 | 3 | 7 | 6 | 7 | 3 |
| Hold | 3 | 4 | 3 | 1 | 0 | 0 |
| Sell | 2 | 2 | 2 | 3 | 2 | 1 |
Earnings and sales forecast
Next report: 09.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.37 (from $0.19 to $0.63). Last quarter: $0.05.
Sales
Next quarter’s sales estimate — $245M (from $232M to $255M). Last quarter: $240M.
Best top-analyst consensus in the sector · Healthcare
About TG Therapeutics
- CEO: Michael S. Weiss
- Employees: 399
- 3020 Carrington Mill Blvd., Morrisville, NY, 27560, US
- www.tgtherapeutics.com
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biothe
Data from the stock’s TipRanks forecast page, read 95 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗